Fnip1 regulates skeletal muscle fiber type specification, fatigue resistance, and susceptibility to muscular dystrophy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 2, 2015, Pages 424-429

  Reyes, Nicholas L ^a   Banks, Glen B ^a   Tsang, Mark ^a   Margineantu, Daciana ^b   Gu, Haiwei ^a   Djukovic, Danijel ^a   Chan, Jacky ^a   Torres, Michelle ^a   Liggitt, H Denny ^a   Hirenallur S, Dinesh K ^a   Hockenbery, David M ^b   Raftery, Daniel ^a,b   Iritani, Brian M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

AMPK; BHD; Folliculin; MTOR; PGC1

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENYLATE KINASE; CELL PROTEIN; CREATINE KINASE; CYTOCHROME B; CYTOCHROME C; DYSTROPHIN; FOLLICULIN INTERACTING PROTEIN 1; GLYCOGEN SYNTHASE KINASE 3; MESSENGER RNA; MYOGLOBIN; MYOSIN HEAVY CHAIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SUCCINATE DEHYDROGENASE; TROPONIN; TROPONIN C1; TROPONIN I; TROPONIN T1; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 3; UTROPHIN; CARRIER PROTEIN; FNIP1 PROTEIN, MOUSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; MYH7 PROTEIN, MOUSE; PPARGC1A PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CELL COUNT; CELL CULTURE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE PREDISPOSITION; DUCHENNE MUSCULAR DYSTROPHY; ENZYME ACTIVATION; GASTROCNEMIUS MUSCLE; MALE; MITOCHONDRION; MOUSE; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE EXERCISE; MUSCLE FATIGUE; MUSCLE FIBRIL; MUSCLE INJURY; MUSCLE NECROSIS; MUSCULAR DYSTROPHY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SKELETAL MUSCLE; SOLEUS MUSCLE; ANIMAL; DEFICIENCY; DISEASE MODEL; FAST MUSCLE FIBER; GENETICS; KNOCKOUT MOUSE; METABOLISM; MUSCLE CONTRACTION; MUSCLE MITOCHONDRION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SLOW MUSCLE FIBER; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

MAMMALIA; MURINAE; MUS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, INBRED MDX; MICE, KNOCKOUT; MITOCHONDRIA, MUSCLE; MULTIPROTEIN COMPLEXES; MUSCLE CONTRACTION; MUSCLE FATIGUE; MUSCLE FIBERS, FAST-TWITCH; MUSCLE FIBERS, SLOW-TWITCH; MUSCULAR DYSTROPHY, DUCHENNE; MYOGLOBIN; MYOSIN HEAVY CHAINS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 84920939857     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1413021112     Document Type: Article

References (44)

1. Schiaffino S, Reggiani C (2011) Fiber types in mammalian skeletal muscles. Physiol Rev 91(4):1447-1531.
2. Stuart CA, et al. (2013) Slow-twitch fiber proportion in skeletal muscle correlates with insulin responsiveness. J Clin Endocrinol Metab 98(5):2027-2036.
3. Hambrecht R, et al. (1997) Effects of endurance training on mitochondrial ultrastructure and fiber type distribution in skeletal muscle of patients with stable chronic heart failure. J Am Coll Cardiol 29(5):1067-1073.
4. Lin J, et al. (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418(6899):797-801.
5. Arany Z, et al. (2007) The transcriptional coactivator PGC-1beta drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab 5(1):35-46.
6. Narkar VA, et al. (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell 134(3):405-415.
7. Hardie DG (2011) Energy sensing by the AMP-activated protein kinase and its effects on muscle metabolism. Proc Nutr Soc 70(1):92-99.
8. Gowans GJ, Hardie DG (2014) AMPK: A cellular energy sensor primarily regulated by AMP. Biochem Soc Trans 42(1):71-75.
9. Wu H, et al. (2002) Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 296(5566):349-352.
10. Naya FJ, et al. (2000) Stimulation of slow skeletal muscle fiber gene expression by calcineurin in vivo. J Biol Chem 275(7):4545-4548.
11. Kramerova I, et al. (2012) Impaired calcium calmodulin kinase signaling and muscle adaptation response in the absence of calpain 3. Hum Mol Genet 21(14):3193-3204.
12. Parsons SA, Wilkins BJ, Bueno OF, Molkentin JD (2003) Altered skeletal muscle phenotypes in calcineurin Aalpha and Abeta gene-targeted mice. Mol Cell Biol 23(12): 4331-4343.
13. Appleby MW, Ramsdell F (2003) A forward-genetic approach for analysis of the immune system. Nat Rev Immunol 3(6):463-471.
14. Park H, et al. (2012) Disruption of Fnip1 reveals a metabolic checkpoint controlling B lymphocyte development. Immunity 36(5):769-781.
15. Baba M, et al. (2006) Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci USA 103(42):15552-15557.
16. Hasumi H, et al. (2008) Identification and characterization of a novel folliculininteracting protein FNIP2. Gene 415(1-2):60-67.
17. Takagi Y, et al. (2008) Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein. Oncogene 27(40):5339-5347.
18. Linehan WM, et al. (2009) Hereditary kidney cancer: Unique opportunity for diseasebased therapy. Cancer 115(10, Suppl):2252-2261.
19. Zong H, et al. (2002) AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci USA 99(25): 15983-15987.
20. Jäger S, Handschin C, St-Pierre J, Spiegelman BM (2007) AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 104(29):12017-12022.
21. Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274-293.
22. Lin J, et al. (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119(1):121-135.
23. Ruegg UT (2013) Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Curr Opin Neurol 26(5):577-584.
24. Koenig M, et al. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50(3):509-517.
25. Hoffman EP, Brown RH, Jr, Kunkel LM (1987) Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51(6):919-928.
26. Monaco AP, et al. (1986) Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323(6089):646-650.
27. Bulfield G, Siller WG, Wight PA, Moore KJ (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 81(4):1189-1192.
28. Im WB, et al. (1996) Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet 5(8):1149-1153.
29. Röckl KS, et al. (2007) Skeletal muscle adaptation to exercise training: AMP-activated protein kinase mediates muscle fiber type shift. Diabetes 56(8):2062-2069.
30. Garcia-Roves PM, Osler ME, Holmström MH, Zierath JR (2008) Gain-of-function R225Q mutation in AMP-activated protein kinase gamma3 subunit increases mitochondrial biogenesis in glycolytic skeletal muscle. J Biol Chem 283(51):35724-35734.
31. Mu J, Brozinick JT, Jr, Valladares O, Bucan M, Birnbaum MJ (2001) A role for AMPactivated protein kinase in contraction-and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 7(5):1085-1094.
32. Reznick RM, et al. (2007) Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab 5(2):151-156.
33. Jørgensen SB, et al. (2007) Role of AMPKalpha2 in basal, training-, and AICAR-induced GLUT4, hexokinase II, and mitochondrial protein expression in mouse muscle. Am J Physiol Endocrinol Metab 292(1):E331-E339.
34. O'Neill HM, et al. (2011) AMP-activated protein kinase (AMPK) beta1beta2 muscle null mice reveal an essential role for AMPK in maintaining mitochondrial content and glucose uptake during exercise. Proc Natl Acad Sci USA 108(38):16092-16097.
35. Thomson DM, et al. (2007) Skeletal muscle and heart LKB1 deficiency causes decreased voluntary running and reduced muscle mitochondrial marker enzyme expression in mice. Am J Physiol Endocrinol Metab 292(1):E196-E202.
36. Rowe GC, Safdar A, Arany Z (2014) Running forward: New frontiers in endurance exercise biology. Circulation 129(7):798-810.
37. Hasumi H, et al. (2012) Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN. J Natl Cancer Inst 104(22):1750-1764.
38. Yan M, et al. (2014) The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation. J Clin Invest 124(6):2640-2650.
39. Possik E, et al. (2014) Folliculin regulates ampk-dependent autophagy and metabolic stress survival. PLoS Genet 10(4):e1004273.
40. Park H, Tsang M, Iritani BM, Bevan MJ (2014) Metabolic regulator Fnip1 is crucial for iNKT lymphocyte development. Proc Natl Acad Sci USA 111(19):7066-7071.
41. Katsetos CD, Koutzaki S, Melvin JJ (2013) Mitochondrial dysfunction in neuromuscular disorders. Semin Pediatr Neurol 20(3):202-215.
42. Webster C, Silberstein L, Hays AP, Blau HM (1988) Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 52(4):503-513.
43. Handschin C, et al. (2007) PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev 21(7):770-783.
44. Chan MC, et al. (2014) Post-natal induction of PGC-1 protects against severe muscle dystrophy independently of utrophin. Skelet Muscle 4(1):2.